A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Epistemonikos ID: 166c1835bcfc4d8182b74988d184a53e1dff10ff
First added on: Mar 01, 2025